Clinical Director, Oncology Clinical Development US Remote

Clinical Director, Oncology Clinical Development

US Remote

Natera is seeking an experienced Clinical Director in Oncology Clinical Development to provide medical and scientific leadership for Natera-sponsored oncology clinical trials focused on minimal residual disease (MRD). In this pivotal role, you’ll drive the design and execution of biomarker-driven interventional and randomized studies that integrate MRD testing into precision oncology strategies to support regulatory, scientific, and strategic objectives.

We’re looking for an innovative clinical leader with deep oncology clinical development experience who thrives in a fast-paced, collaborative environment—and who’s passionate about transforming cancer care.

Natera’s MRD platform is redefining precision oncology—enabling earlier detection, improved monitoring, and smarter treatment decisions. In this role, you’ll lead studies that directly shape how cancer is managed worldwide, bringing actionable insights to clinicians and patients when they matter most.

• Serve as the program-level medical lead for Natera-sponsored MRD clinical trials across assigned oncology indications, with ultimate accountability for clinical outcomes, data integrity, and patient safety.
• Define clinical development strategies that align study design, endpoints, and execution with regulatory and scientific objectives.
• Provide medical oversight across the full trial lifecycle, from design and protocol development through first patient in (FPI), data readout, and study close-out.

• Provide strategic and medical guidance to Clinical Scientists, fostering collaboration on protocol design, data interpretation, and translational insights that drive clinical program success.
• Act as Medical Monitor, overseeing safety signal detection, adverse event review, and risk mitigation in compliance with GCP and regulatory requirements.

• Partner cross-functionally with Clinical Science, Clinical Operations, Data Management and Biostatistics to ensure timely and successful study execution, operational feasibility, and data quality.
• Collaborate with Regulatory Affairs to support submissions, regulatory interactions, and responses, as appropriate.

• Represent Natera as the clinical development lead in interactions with investigators, key opinion leaders, IRBs, and regulatory authorities.
• Guide interpretation of interim and final analyses, ensuring scientific accuracy and clinical relevance.
• Provide strategic leadership for clinical study reports, and other required study-related clinical and regulatory documentation in collaboration with cross-functional partners.
• Lead authorship and strategy for manuscripts, abstracts, and conference presentations in collaboration with Clinical Science, Biostatistics, Translational Medicine and Scientific Communications.

• Shape and influence the evolution of Natera’s Clinical Development organization by establishing governance standards, decision frameworks, and best practices that ensure high-quality, audit-ready execution across sponsored studies.
• Provide senior-level mentorship and clinical leadership to Clinical Scientists, enabling consistent application of scientific rigor and regulatory standards across clinical programs.

• MD (or equivalent)
• ≥3 years of industry experience in oncology clinical development.
• Demonstrated experience serving as Medical Monitor or clinical lead for Phase II–III studies.
• Strong working knowledge of GCP, ICH guidelines, and regulatory expectations for interventional trials.
• Proven ability to interpret and communicate complex clinical data to internal and external stakeholders.

• Board certification in Medical Oncology or Hematology/Oncology.
• Experience with biomarker-driven development, molecular diagnostics, or MRD-focused programs.
• Prior involvement in regulatory interactions (e.g., FDA meetings, briefing documents).
• Experience working within matrixed clinical development organizations.

The pay range is listed and actual compensation packages are based on a wide…